Verrica Pharmaceuticals Inc. (VRCA) Tops Q4 EPS by 6c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q4 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $340 thousand versus the consensus estimate of $532.75 thousand.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• Bending Spoons (BSP) indicating to open at $32, IPO priced at $29
• UBS Reiterates Buy Rating on Constellation Brands (STZ) Following Q1 Results
• B.Riley on Oklo (OKLO): 'Takes Another Step Toward Criticality Milestone for Isotopes Reactor'